News & Events about Dynavax Technologies Corporation.
Saint-Herblain (France), December 30, 2022 Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported further heterologous booster data from an exploratory, small clinical study for its inactivated COVID-19 vaccine, VLA2001. In study VLA2001-3071, a subset of ...
Dynavax Technologies Co. (NASDAQ:DVAX Get Rating) Director Andrew A. F. Hack sold 1,500,000 shares of the stock in a transaction dated Tuesday, December 6th. The shares were sold at an average price of $11.60, for a total transaction of $17,400,000.00. Following the completion of the transaction, ...
Yousif Capital Management LLC acquired a new stake in Dynavax Technologies Co. (NASDAQ:DVAX Get Rating) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 108,179 shares of the biopharmaceutical companys stock, valued at ...
Globe Newswire
3 months ago
-- Significant progress made on regulatory submissions to the China NMPA, the EMA, and the WHO for Clovers lead COVID-19 vaccine candidate, SCB-2019 (CpG 1018/Alum), with completion anticipated in Q4 2022-- -- New data demonstrating superiority as a heterologous booster compared to inactivated ...
Globe Newswire
4 months ago
Saint-Herblain (France), September 26, 2022 Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced a further update on its COVID-19 vaccine activities. The Company had previously communicated that it would invest in further development of a potential second-...